Australia-based Cynata Therapeutics has secured ethics committee approval to conduct a clinical trial of its Cymerus mesenchymal stem cells (MSCs) to treat adult Covid-19 patients admitted to intensive care.
Called MEND, the open-label, randomised controlled trial will assess early efficacy of Cymerus MSCs. It builds on the company’s positive pre-clinical study results in ARDS, sepsis and cytokine release syndrome, which are known characteristics of severe Covid-19.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study will be performed at sites in New South Wales in alliance with the Cerebral Palsy Alliance Research Institute and the Covid-19 Stem Cell Treatment (CSCT) Group investigators.
